000169962 001__ 169962
000169962 005__ 20240229133701.0
000169962 0247_ $$2doi$$a10.3390/cancers13143451
000169962 0247_ $$2pmid$$apmid:34298664
000169962 0247_ $$2altmetric$$aaltmetric:109915568
000169962 037__ $$aDKFZ-2021-01662
000169962 041__ $$aEnglish
000169962 082__ $$a610
000169962 1001_ $$00000-0003-3894-5053$$aHau, Peter$$b0
000169962 245__ $$aDevelopment of Randomized Trials in Adults with Medulloblastoma-The Example of EORTC 1634-BTG/NOA-23.
000169962 260__ $$aBasel$$bMDPI$$c2021
000169962 3367_ $$2DRIVER$$aarticle
000169962 3367_ $$2DataCite$$aOutput Types/Journal article
000169962 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1641137937_5855$$xReview Article
000169962 3367_ $$2BibTeX$$aARTICLE
000169962 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169962 3367_ $$00$$2EndNote$$aJournal Article
000169962 520__ $$aMedulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemotherapy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (OdomzoTM, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be translated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.
000169962 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000169962 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169962 650_7 $$2Other$$aadult
000169962 650_7 $$2Other$$acerebrospinal fluid
000169962 650_7 $$2Other$$achemotherapy
000169962 650_7 $$2Other$$aclinical trial
000169962 650_7 $$2Other$$amagnetic resonance imaging
000169962 650_7 $$2Other$$amedulloblastoma
000169962 650_7 $$2Other$$aradiotherapy
000169962 650_7 $$2Other$$arandomized
000169962 650_7 $$2Other$$asubgrouping
000169962 650_7 $$2Other$$atargeted therapy
000169962 7001_ $$aFrappaz, Didier$$b1
000169962 7001_ $$00000-0002-9973-9360$$aHovey, Elizabeth$$b2
000169962 7001_ $$00000-0002-5138-0707$$aMcCabe, Martin G$$b3
000169962 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian W$$b4$$udkfz
000169962 7001_ $$aWiestler, Benedikt$$b5
000169962 7001_ $$aSeidel, Clemens$$b6
000169962 7001_ $$aCombs, Stephanie E$$b7
000169962 7001_ $$aDirven, Linda$$b8
000169962 7001_ $$aKlein, Martin$$b9
000169962 7001_ $$00000-0002-5495-6062$$aAnazodo, Antoinette$$b10
000169962 7001_ $$00000-0002-8392-9004$$aHattingen, Elke$$b11
000169962 7001_ $$aHofer, Silvia$$b12
000169962 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b13$$udkfz
000169962 7001_ $$aZimmer, Claus$$b14
000169962 7001_ $$aKortmann, Rolf-Dieter$$b15
000169962 7001_ $$aSunyach, Marie-Pierre$$b16
000169962 7001_ $$aTanguy, Ronan$$b17
000169962 7001_ $$aEffeney, Rachel$$b18
000169962 7001_ $$0P:(DE-HGF)0$$avon Deimling, Andreas$$b19
000169962 7001_ $$0P:(DE-HGF)0$$aSahm, Felix$$b20
000169962 7001_ $$0P:(DE-HGF)0$$aRutkowski, Stefan$$b21
000169962 7001_ $$aBerghoff, Anna S$$b22
000169962 7001_ $$00000-0001-9332-4677$$aFranceschi, Enrico$$b23
000169962 7001_ $$00000-0003-2128-747X$$aPineda, Estela$$b24
000169962 7001_ $$00000-0002-3336-157X$$aBeier, Dagmar$$b25
000169962 7001_ $$aPeeters, Ellen$$b26
000169962 7001_ $$aGorlia, Thierry$$b27
000169962 7001_ $$aVanlancker, Maureen$$b28
000169962 7001_ $$aBromberg, Jacoline E C$$b29
000169962 7001_ $$aGautier, Julien$$b30
000169962 7001_ $$00000-0001-7451-7916$$aZiegler, David S$$b31
000169962 7001_ $$aPreusser, Matthias$$b32
000169962 7001_ $$0P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aWick, Wolfgang$$b33$$udkfz
000169962 7001_ $$00000-0002-1748-174X$$aWeller, Michael$$b34
000169962 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers13143451$$gVol. 13, no. 14, p. 3451 -$$n14$$p3451$$tCancers$$v13$$x2072-6694$$y2021
000169962 909CO $$ooai:inrepo02.dkfz.de:169962$$pVDB
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b21$$kDKFZ
000169962 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)92e9783ca7025f36ce14e12cd348d2ee$$aDeutsches Krebsforschungszentrum$$b33$$kDKFZ
000169962 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000169962 9141_ $$y2021
000169962 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2019$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-04
000169962 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2019$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-05-04
000169962 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-05-04
000169962 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x0
000169962 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x1
000169962 9201_ $$0I:(DE-He78)B320-20160331$$kB320$$lKKE Neuroonkologie$$x2
000169962 980__ $$ajournal
000169962 980__ $$aVDB
000169962 980__ $$aI:(DE-He78)HD01-20160331
000169962 980__ $$aI:(DE-He78)B062-20160331
000169962 980__ $$aI:(DE-He78)B320-20160331
000169962 980__ $$aUNRESTRICTED